Interview with Aihua Pan, Chairman, SinoBioway Group
Could you provide us with an introduction to the company and an overview of operations from the company’s founding through to your position today as a leading biotech company in…
Address: PKU Biocity No. 39 ShangDiXi Lu, Haidian, Beijing, P.R. China
Tel: 86 10 8289 0924
SinoBioway Group Co., Ltd. was founded in 1992 and is one of the three major industry groups of Beijing University. It is mainly engaged in bio-industry development and the establishment of bio-economic systems with a focus on investment in three main areas: bio-medicine, bio-agriculture and bio-services. After more than ten years of dedication, the group has become China’s most influential and modern bio-enterprise.
The group now owns three main facilities: Beijing University Biological City, Beijing University Biological Park at Xiamen and Guangzhou Liuxi Biological Bay. Additionally, the group operates multiple holding subsidiaries such as Beijing Sinovac Biotech Co., Ltd., Xiamen Bioway-PKU Biotech Co., Ltd., Guangzhou Weiming Biotech Co., Ltd., Weiming Nature Unity Chinese Medicine Co., Ltd. and Beijing Weiming Kaituo Agricultural Biotech Ltd.
The main products of SinoBioway include an injection of mouse-nerve growth factor (Nobex ®), an inactivated hepatitis A vaccine (Healive ®), a hepatitis B vaccine (Bilive ®), anti-flu vaccines (Anflu ®, Panflu ®, and Panflu.1 ®), as well as hundreds of kinds of Chinese medicinal granules. The group now has established a fairly complete R & D system with centers for: Bio-Pharmaceutical Research, Vaccine Research, National Crop Molecular Design, Bio-Intelligence Research, Bio-Economic Research. It operates various institutions and R & D platforms while employing a group of outstanding research personnel.
Having researched mainly for the bio-economy, biological drugs (generic drugs and peptide drugs), human vaccines, modern Chinese medicine, molecular crop breeding, biomass energy and bio-intelligence technology, the group has achieved a series of major breakthroughs. These include the successful development and production of the world’s first drug treatment of traumatic nerve injury – the “nerve growth factor”, the world’s first “inactivated vaccine targeting SARS virus”, and China’s first “human-use influenza vaccine”. The world’s first influenza A (H1N1) vaccine -Panflu.1 ® was successfully produced on September 3, 2009. The group has initiated the world’s first “bio-economy incubator” (an efficient R & D system of new drugs), established a theoretical system of bio-economy, created an economic bio-restructuring model, and carried out a preliminary study of bio-industry development ideas suitable for China’s national conditions.
SinoBioway has engaged in corporate restructuring and through government guidance has shifted to a market approach. At the moment, the group has formed five industry groups on the basis of existing enterprises which include: vaccines, traditional Chinese medicine, bio-pharmaceuticals, modern agriculture and biological services. Through forming bio-economic systems in the industrial, R & D and financial arena, the group aims to build SinoBioway into a flagship company for the bio-economy era.
vaccines, traditional Chinese medicine, bio-pharmaceuticals
Could you provide us with an introduction to the company and an overview of operations from the company’s founding through to your position today as a leading biotech company in…
Simon, you established Glory Medical back in 1998. What was the main rationale behind this significant decision? “We already have operations in Sri Lanka and Pakistan, and are exploring projects…
Dr. Chen Hao is the CEO and founder of the promising startup Imsight, the only company focusing on medical imaging analysis using Artificial Intelligence technology in the Greater Bay Area.…
Alex Wang Yimin, founder and CEO of SONTU Medical Imaging, shares the exciting story of SONTU’s development since 2009, their significant investment into R&D and various international certifications like the…
Dr. Lu Xianping is the founder and now Chairman and CEO of one of China’s few truly innovative biotech companies, ChipScreen BioSciences Co. In this exciting interview, he shares the…
Scott Liang, president of Apex (Guangzhou) Tools and Orthopedics discusses the company’s strong positioning on the Chinese medtech market, current strategic priorities, and what differentiates Apex from its competitors. As…
Dami Qiu, founder and CEO of EMP, shares her personal story of how she decided to establish EMP two decades ago, the market opportunities in ultrasound medical equipment in China,…
In this unique interview, Dr. David Peng, CEO of Medical Excellence International (China), shares the company´s foundations, its key milestones as well as its two unique membership programs. He further…
Sheng Sitong, founder and CEO of gene sequencing device company, Considerin Group (formerly HYK Gene), discusses Considerin’s rapid expansion and the development of precision medicine in China. Mr. Sheng, could…
Yuan Qing, President of the Shenzhen Life Science and Biotechnology Association, shares his insights on the characteristics of the life sciences environment in Shenzhen, the importance of the sectors as…
Guangdong province and neighbouring Hong Kong have long been fundamental to China’s metamorphosis into an economic superpower. Notable as one of the country’s most open and dynamic regions, the Pearl…
One of the more eye-catching and ambitious initiatives to come out of last March’s National People’s Congress, Premier Li Keqiang’s grand vision for the cultivation of a globally competitive cluster…
One of China’s biggest vaccine manufacturers was found to have falsified rabies vaccine records causing nationwide parenting chaos. Executives from China’s second largest pharmaceutical company, ChangSheng biotechnology (Changsheng literally translates…
See our Cookie Privacy Policy Here
